Advertisement

Surgical equipment maker Conmed Corp. said Friday that the Food and Drug Administration has approved its Altrus thermal-energy based tissue fusion system.

The Utica, N.Y., company said it expects modest revenue of between $5 million and $10 million next year for the system, but it should be a contributor to long-term growth.

The Altrus Thermal Tissue Fusion System uses thermal energy to seal, cut, grasp and dissect vessels up to 7 millimeters in size.

Conmed shares climbed 15 cents to $23.25 in Friday morning trading.

Advertisement
Advertisement